Fibronectin based scaffold proteins having improved stability
The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
1. A nucleic acid encoding a fibronectin-based protein dimer comprising a first fibronectin type III tenth ( 10 Fn3) domain and a second 10 Fn3 domain, wherein each of the first 10 Fn3 domain and the second 10 Fn3 domain:
(i) comprises an AB loop, a BC loop, a CD loop, a DE loop, an EF loop, and a FG loop, wherein the first and second 10 Fn3 domains have at least one loop selected from the BC, DE, and FG loops with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain having the amino acid sequence of SEQ ID NO: 1;
(ii) comprises an amino acid sequence having at least 60% identity to SEQ ID NO: 1 and binds to a target molecule; and
(iii) comprises a C-terminal tail consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35.
2. The nucleic acid of claim 1 , wherein the first 10 Fn3 domain and the second 10 Fn3 domain bind to different targets.
3. The nucleic acid of claim 1 , wherein the first 10 Fn3 domain and the second 10 Fn3 domain are connected by a polypeptide linker comprising 1-30 amino acids.
4. The nucleic acid of claim 3 , wherein the linker is selected from the group consisting of: a glycine-serine based linker, a glycine-proline based linker, a proline-alanine linker, and an Fn-based linker.
5. The nucleic acid of claim 1 , wherein the protein dimer has less than 4% fragmentation during storage in solution at pH 4.0 for at least 4 weeks.
6. The nucleic acid of claim 1 , wherein the protein dimer further comprises one or more pharmacokinetic (PK) moieties selected from the group consisting of: a human serum albumin binding protein, human serum albumin, transferrin, and an Fc fragment.
7. A vector comprising the nucleic acid of claim 1 .
8. A host cell comprising the vector of claim 7 .
9. The host cell of claim 8 , wherein the cell is a bacterial cell.
10. The host cell of claim 8 , wherein the cell is a mammalian cell.